BUSINESS

Competition in the oncology therapeutic area to which IBI-305 belongs is extremely
fierce given the abundance of existing competing drugs and drug candidates that continue to
increase competition in the market. The following table sets forth comparisons between
IBI-305 and its competitive drug candidates in China which are approved to market or in late
stage clinical trials:

Comparison Between IBI-305 and its Approved or Late-Stage Competitors in China

Generic

(Brand) Name/

Drug Code

IBI-305

Bevacizumab

(Avastin)

HLX04
QL1101

GB222
MIL60

LY01008

BP102

TAB008

BAT1706

Filing

Status in
China

Phase 3

Company
Innovent

Date*

2016/11/17

Mechanism
of Action
Anti-VEGF

Lead/Proposed

Retail Price

Indications
R/r NSCLC and

metastatic CRC

(RMB)

N.A.

NRDL/PRDL(1)
N.A.

Roche

Marketed

2010/2/26

Anti-VEGF

Metastatic CRC and

1,998/100 mg

List B

advanced r/r
NSCLC

Henlius
Qilu

Genor
Beijing

mAbworks

Shandong

Boan
Hengrui

TOT

Biopharm

Bio-Thera
Solutions

Phase 3
NDA

submission

Phase 3
Phase 3

2018/3/18
2018/8/15

Anti-VEGF
Anti-VEGF

Metastatic CRC
NSCLC

2017/12/15
2017/8/4

Anti-VEGF
Anti-VEGF

NSCLC
A/R non-squamous

NSCLC

Phase 3

2018/1/28

Anti-VEGF

NSCLC

Phase 3

2018/3/27

Anti-VEGF

Non-squamous

NSCLC

N.A.
N.A.

N.A.
N.A.

N.A.

N.A.

Phase 3

2017/5/17

Anti-VEGF

A/R non-squamous

N.A.

NSCLC

Phase 3

2017/10/31

Anti-VEGF

Non-squamous

N.A.

NSCLC

N.A.
N.A.

N.A.
N.A.

N.A.

N.A.

N.A.

N.A.

Source: Frost & Sullivan

Abbreviation: NRDL = national reimbursement drug list of China; PRDL = provincial reimbursement drug list;

“N.A.” means, with respect to retail price, not available, and with respect to NRDL/PRDL, not applicable because
the drug candidate is not marketed yet.

*

(1)

for a marketed product, it refers to the NMPA approval date; for a clinical stage product, it refers to the date
when the information about clinical trials is published for the first time (首次公示日期); for a product with
NDA submitted and the NDA result pending, it refers to the date of NDA submission.

Bevacizumab are included in the NRDL List B Catalogue. As Bevacizumab entered into the NRDL List B
Catalogue via price negotiation, it will automatically be added into the PRDLs when each provinces and
municipalities updates its PRDL according to Notice on Inclusion of 36 Drugs in NRDL List B Catalogue for
National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (《關於將36種藥品納入國
家基本醫療保險、工傷保險和生育保險藥品目錄乙類範圍的通知》). As of August 9, 2018, eight provinces
and municipalities, including Heilongjiang, Shanghai, Henan, Jilin, Jiangxi, Shandong, Jiangsu and Liaoning,
have recently updated their PRDLs to include bevacizumab as a List B drug.

– 246 –

